12:00 AM
Jun 01, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TH-302: Phase I/II data

Interim data from 30 evaluable patients in the dose-escalation Phase I part of the U.S. Phase I/II TH-CR-402 trial showed that 240-480 mg/m 2 weekly IV TH-302 in combination with one of Gemzar, Alimta or Taxotere produced 7 partial responses...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >